Browsing Clinical Studies by author "Catovsky, Daniel"
Now showing items 1-20 of 37
-
A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders
Sah, SP; Matutes, E; Wotherspoon, AC; Morilla, R; Catovsky, D (2003-02)Aims: To evaluate the diagnostic value of bone marrow aspirates, trephine biopsies (BMB), and flow cytometry (FC) in the assessment of bone marrow infiltration in chronic lymphoid disorders. Methods: Investigations were ... -
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgV(H) genes and includes patients with good prognosis, nonnodal disease
Orchard, J; Garand, R; Davis, Z; Babbage, G; Sahota, S; et al. (AMER SOC HEMATOLOGY, 2003-06-15)We analyzed lymphocyte morphology, histology, immunophenotype, immunoglobulin heavy chain (IgV(H)) gene mutations, and clinical course in 80 unselected patients presenting with circulating t(11;14) lymphocytes. Of the 80 ... -
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
Catovsky, D; Matutes, E (2012-05)Purpose In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In contrast, TP53 defects are not associated with resistance ... -
Alemtuzumab in T-cell malignancies
Dearden, CE; Matutes, E; Catovsky, D (HUMANA PRESS INC, 2002)Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen, which is abundantly expressed on all normal and most malignant T-lymphocytes. We summarize the results of our experience using alemtuzumab ... -
B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia
Ruchlemer, R; Parry-Jones, N; Brito-Babapulle, V; Attolico, I; Wotherspoon, AC; et al. (BLACKWELL PUBLISHING LTD, 2004-05)We reviewed eight cases that were diagnosed before 1995 with B-prolymphocytic leukaemia (B-PLL) harbouring t(11;14)(q13;q32) and/or cyclin D1 staining. Thirteen B-PLL patients without t(11;14) were selected as controls. ... -
Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif
Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR (2002-01-17)The mature sporadic T-cell malignancy, T-cell prolymphocytic leukemia (T-PLL) is remarkable for frequently harbouring somatic mutations of the Ataxia Telangiectasia (A-T) gene, ATM. Because some data suggest ATM is frequently ... -
CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease
Scolnik, MP; Morilla, R; Bracco, MMDED; Catovsky, D; Matutes, E (2002)We estimated by quantitative flow cytometry (FC) the expression of CD13, CD33, CD34 and CD117 antigens in cells from 64 patients with acute myeloid leukaemia (AML) and 22 normal bone marrows (BMs). The method converts ... -
CD52 expression in T-cell large granular lymphocyte leukemia - Implications for treatment with alemtuzumab
Osuji, N; Del Giudice, I; Matutes, E; Morilla, A; Owusu-Ankomah, K; et al. (TAYLOR & FRANCIS LTD, 2005-05)Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not ... -
Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma
Trøen, G; Nygaard, V; Jenssen, T-K; Ikonomou, IM; Tierens, A; et al. (2004)Splenic marginal zone lymphoma (SMZL) is a lymphoma type of putative marginal zone B-cell origin. No specific genetic alterations have yet been demonstrated in SMZL. Clinically, SMZL is a low-grade B-cell non-Hodgkin ... -
Cutaneous findings in chronic lymphocytic leukaemia
Agnew, KL; Ruchlemer, R; Catovsky, D; Matutes, E; Bunker, CB (BLACKWELL PUBLISHING LTD, 2004-06)Background Chronic lymphocytic leukaemia (CLL) is a malignancy characterized by clonal expansion of B lymphocytes with distinct morphology and immunophenotype. The dermatological literature relating to CLL is sparse. A ... -
Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies
Elnenaei, MO; Jadayel, DM; Matutes, E; Morilla, R; Owusu-Ankomah, K; et al. (2001)The translocation (11;14)(q13;q32) and its molecular counterpart the BCL-1 rearrangement are features observed in mantle cell lymphoma (MCL) and less commonly in other B-cell disorders. This rearrangement leads to cyclin ... -
Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH
Parry-Jones, N; Matutes, E; Morilla, R; Brito-Babapulle, V; Wotherspoon, A; et al. (BLACKWELL PUBLISHING, 2007-04)Mantle cell lymphoma (MCL), characterised by t(11;14)(q13;q32), has a poor prognosis. Many cases have additional cytogenetic abnormalities, and often have a complex karyotype. Fluorescence in situ hybridisation (FISH) was ... -
Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes
Gruszka-Westwood, AM; Hamoudi, R; Osborne, L; Matutes, E; Catovsky, D (WILEY-LISS, 2003-01)Splenic lymphoma with villous lymphocytes (SLVL) is a low-grade lymphoproliferative disorder characterized by splenomegaly and circulating villous lymphocytes in the peripheral blood. It is considered to be the leukemic ... -
Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia
Brito-Babapulle, V; Baou, M; Matutes, E; Morilla, R; Atkinson, S; et al. (BLACKWELL SCIENCE LTD, 2001-08)Deletions of 13q14.3 are well known in several malignancies and are thought to be associated with tumour suppressor function. The RB-1 gene is a tumour suppressor gene, but other loci including D13S319 and D13S25 telomeric ... -
Delineation of the minimal region of loss at 13q14 in multiple myeloma
Elnenaei, MO; Hamoudi, RA; Swansbury, J; Gruszka-Westwood, AM; Brito-Babapulle, V; et al. (2003-01)Previous studies have focused on the incidence and prognostic implications of 13q14 deletions in multiple myeloma (MM), but none has sought to delineate the minimal common deleted region (CDR). In an effort to do so, ... -
Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry
Jain, P; Giustolisi, GM; Atkinson, S; Elnenaei, MO; Morilla, R; et al. (BRITISH MED JOURNAL PUBL GROUP, 2002-12)Aims: To describe and revise a flow cytometric assay for evaluating cyclin D1 overexpression in B cell lymphoproliferative disorders (B-LPDs), Methods: Cyclin D1 expression was evaluated in 11 healthy controls and 5 1 ... -
Diagnostic issues in chronic lymphocytic leukaemia (CLL)
Matutes, E; Catovsky, D (ELSEVIER SCI LTD, 2010-03)The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the initial diagnostic investigations. In atypical cases, these tests should be complemented ... -
Diagnostic significance of CD20 and FMC7 expression in B-cell disorders
Delgado, J; Matutes, E; Morilla, AM; Morilla, RM; Owusu-Ankomah, KA; et al. (AMER SOC CLINICAL PATHOLOGY, 2003-11)We analyzed by flow cytometry the expression of CD20 and FMC7 in cell suspensions from 932 patients, including 630 cases of chronic lymphocytic leukemia (CLL), 23 cases of other B-cell leukemias, and 279 cases of B-cell ... -
Differential diagnosis in chronic lymphocytic leukaemia
Matutes, E (ELSEVIER SCIENCE BV, 2007-09)The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the key initial diagnostic tests. In cases with atypical features, these investigations ... -
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin’s lymphoma
Hendry, L; Bowen, A; Matutes, E; Swansbury, J; Catovsky, D (TAYLOR & FRANCIS LTD, 2004-05)A regimen combining fludarabine, cyclophosphamide and mitoxantrone (FCM) was used to treat 29 patients with relapsed or refractory chronic lymphocytic leukemia (CLL, N= 24) and low-grade non-Hodgkin’s lymphoma (NHL, N= 5) ...